Wednesday, 13 Nov 2019

You are here

RheumNow Podcast – TNFs and the Inflammasome (1.25.19)

Dr Jack Cush reviews the news from the past week at RheumNow.com.

  1. Meta-analysis of 4719 elderly RA/IBD/PSO pts on biologics vs 13,305 younger vs 3961 older patients (no biologics) shows biologic use in elderly to be assoc w/ an increased risk of infections (3.6 fold increase in risk) but no increase in cancer or death https://t.co/pWtMMo2KQ1
  2. Using FMF-KI knockout mice (high TNF levels) researchers find TNF signaling drives pyrin & inflammasome activation; TNF is a critical modulator of pyrin of pyrin-inflammasomopathies like FMF. This is why TNF inhib sometimes work in inflammasomopathies. https://t.co/0EvuTI57tn
  3. Systematic review of literature and 478 RA patients (mostly female; age 53-64 yrs) shows 73 to 97% of patients being unaware of an increased risk of developing Cardiovascular Disease in relation to their RA, https://t.co/aNM3wI2KBo
  4. JAMA study shows that when drug companies increased their opioid marketing budgets by just $5.29 per 1,000 population, the number of MD opioid prescriptions went up 82% and opioid deaths increased 9%. https://t.co/4FAr53gH17 
  5. Using the 1998-2014 U.S. National Inpatient Sample- gout was associated with 9-20% higher healthcare utilization and 6% higher hazard of transfusion after primary hip replacement surgery. https://buff.ly/2U8wvwu
  6. Does Seropositivity Change with Therapy?
  7. Smoking Doesn't Influence Rituximab Responses in Rheumatoid Arthritis

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

New EMA Warnings for Tofacitinib in Patients at Risk for Clots

The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.

FDA Approves Ustekinumab for Ulcerative Colitis

Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.

Interleukin Targeted Biologics Increase Risks of Infection

A systematic review of the literature shows that, compared to placebo, the use of non-TNF, interleukin inhibitor biologics may be associated with significantly higher rates of serious infections, opportunistic infections, and cancer.

Biologics Lead the Way in Drug Price Increases

Reuters has reported the results of a recent Institute for Clinical and Economic Review (ICER) analysis showing that biologics, especially Humira and Rituxan, are leading the way in the cost of drugs in the USA. All told, Humira and Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. drug spending. ICER said their analysis points to price hikes that were more than twice the rate of medical inflation and were not warranted by any new clinical evidence.

Ustekinumab Efficacy in Ulcerative Colitis

The NEJM reports the results of a one year trial wherein ustekinumab (UST) was shown to be effective at inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. Ustekinumab, currently approved for use in psoriasis, psoriatic arthritis and Crohn's disease, is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23.